Description du projet
Prévoir l’évolution depuis l’inflammation à la maladie
L’inflammation chronique est la cause de nombreuses maladies, car elle endommage silencieusement les organes. L’identification de biomarqueurs capables de prédire l’inflammation avant l’apparition des symptômes et de fournir une stratification des risques avant l’apparition de la maladie s’avèrerait d’une très grande utilité. Dans cette optique, le projet IMMEDIATE, financé par l’UE, cherche à identifier des biomarqueurs cliniques et omiques dans le but de générer un score de risque de progression/résilience de la maladie. Ses travaux s’intéresseront au rôle des métabolites du microbiote intestinal dans la fonction du système immunitaire et l’inflammation. En outre, les chercheurs étudieront les répercussions sur la santé et le bien-être de la modulation du microbiote intestinal par les probiotiques. Leurs résultats jetteront les bases d’un mode de vie plus sain.
Objectif
IMMEDIATE aims to investigate and explore the diet-microbiome-immunometabolism-axis as a sensor for health-to-disease transition and evaluate strategies to maintain an individual’s well-being. Chronic inflammation is the major root of most diseases. Understanding of this process preceding organ dysfunction or damage and identification of biomarkers in the pre-symptomatic stage and risk but also resilience factors of health-to-disease transition will enable targeted and personalized interventions to prevent irreversible organ damage. Metabolites of gut microbiota are key messengers between diet, microbiota and host, maintaining the balance of pro- and anti-inflammation. Our study takes advantage of cutting-edge omics technologies available within the IMMEDIATE consortium in conjunction with available clinical data and biospecimens from ongoing observational studies, enrolling “healthy” subjects and individuals in the pre-disease stage but with largely distinct environmental and dietary modulators, including a cohort of kidney transplant recipients in whom renal function has been “reset to baseline”. The identification of clinical and omics-derived biomarkers will – by employing AI algorithms - yield a personalized risk / resilience score of chronic inflammation and thus a better prediction of an individual’s risk of transition towards disease. A proof-of-concept intervention study with the anti-inflammatory microbe Akkermansia muciniphila will be conducted to test whether deflections of the microbiome-metabolite-immune axis can be reverted on the biomarker level but also with respect to clinical outcomes and overall well-being. Mobile apps developed by the IMMEDIATE consortium in collaboration with patient organizations tracking numerous lifestyle-related measures and providing guidance and feedback on these aspects will empower individuals to adopt and integrate these knowledge-based health interventions into their own lives, hereby self-managing their own health.
Champ scientifique
Mots‑clés
Programme(s)
Régime de financement
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinateur
10117 Berlin
Allemagne